Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
52.37
+2.31 (4.61%)
At close: Aug 13, 2025, 4:00 PM
51.53
-0.84 (-1.60%)
Pre-market: Aug 14, 2025, 9:12 AM EDT
Celcuity Employees
Celcuity had 87 employees as of December 31, 2024. The number of employees increased by 32 or 58.18% compared to the previous year.
Employees
87
Change (1Y)
32
Growth (1Y)
58.18%
Revenue / Employee
n/a
Profits / Employee
-$1,461,656
Market Cap
2.13B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CELC News
- 7 days ago - Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call - GlobeNewsWire
- 14 days ago - Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst - Seeking Alpha
- 15 days ago - Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 16 days ago - Celcuity: What's Happening With CELC Stock? - Forbes
- 16 days ago - Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewsWire
- 16 days ago - Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz
- 17 days ago - Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - Reuters
- 17 days ago - Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - GlobeNewsWire